Rational design and protein engineering of growth factors for regenerative medicine and tissue engineering.

Growth factors provide key instructive cues for tissue formation and repair. However, many natural growth factors are limited in their usefulness for tissue engineering and regenerative applications by their poor retention at desired sites of action, short half-lives in vivo, pleiotropic actions and other features. In the present article, we review approaches to rational design of synthetic growth factors based on mechanisms of receptor activation. Such synthetic molecules can function as simplified ligands with potentially tunable specificity and action. Rational and combinatorial protein engineering techniques allow introduction of additional features into these synthetic growth molecules, as well as natural growth factors, which significantly enhance their therapeutic utility.

[1]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[2]  Bruce Tidor,et al.  Progress in computational protein design. , 2007, Current opinion in biotechnology.

[3]  Alan Wells,et al.  Engineering epidermal growth factor for enhanced mitogenic potency , 1996, Nature Biotechnology.

[4]  K. Claffey,et al.  Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. , 2006, Biomaterials.

[5]  J. Hubbell,et al.  Development of growth factor fusion proteins for cell‐triggered drug delivery , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  David J. Mooney,et al.  Polymeric Growth Factor Delivery Strategies for Tissue Engineering , 2003, Pharmaceutical Research.

[7]  Jeffrey A. Hubbell,et al.  Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth , 2004, Circulation research.

[8]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[9]  J. Haugh.  Mathematical Model of Human Growth Hormone (hGH)‐Stimulated Cell Proliferation Explains the Efficacy of hGH Variants as Receptor Agonists or Antagonists , 2004, Biotechnology progress.

[10]  David J Mooney,et al.  New materials for tissue engineering: towards greater control over the biological response. , 2008, Trends in biotechnology.

[11]  J. Wells,et al.  Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. , 1999, Biochemistry.

[12]  Y. Ito,et al.  Differential control of cellular gene expression by diffusible and non-diffusible EGF. , 2001, Journal of biochemistry.

[13]  O. Matsushita,et al.  Collagen-binding growth factors: production and characterization of functional fusion proteins having a collagen-binding domain. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Eguchi,et al.  Establishment of a Functionally Active Collagen-Binding Vascular Endothelial Growth Factor Fusion Protein In Situ , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Sung Hyun Kim,et al.  COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Iwata,et al.  Oriented immobilization of epidermal growth factor onto culture substrates for the selective expansion of neural stem cells. , 2007, Biomaterials.

[17]  Barbara Baird,et al.  Trivalent ligands with rigid DNA spacers reveal structural requirements for IgE receptor signaling in RBL mast cells. , 2007, ACS chemical biology.

[18]  C. Cho,et al.  Construction of a Novel Extracellular Matrix using a New Genetically Engineered Epidermal Growth Factor Fused to IgG-Fc , 2005, Biotechnology Letters.

[19]  P. H. Hansen,et al.  Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[21]  J. Kuriyan,et al.  Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast , 2005, Proteins.

[22]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[23]  D. Lauffenburger,et al.  Integrating cell-level kinetic modeling into the design of engineered protein therapeutics , 2005, Nature Biotechnology.

[24]  E. Brogi,et al.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.

[25]  Malgorzata Zakrzewska,et al.  Design of fully active FGF-1 variants with increased stability. , 2004, Protein engineering, design & selection : PEDS.

[26]  Yoshihiro Ito,et al.  Covalently immobilized biosignal molecule materials for tissue engineering. , 2007, Soft matter.

[27]  S. Elliott,et al.  Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. , 2005, Journal of pharmaceutical sciences.

[28]  L. Salvati,et al.  Bioactive surfaces via immobilization of self-assembling polymers onto hydrophobic materials. , 1999, Bioconjugate chemistry.

[29]  S. Hubbard,et al.  Receptor tyrosine kinases: mechanisms of activation and signaling. , 2007, Current opinion in cell biology.

[30]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[31]  Yoshihiro Ito,et al.  A fusion protein of hepatocyte growth factor for immobilization to collagen. , 2007, Biomaterials.

[32]  M. Lehmann,et al.  Engineering proteins for thermostability: the use of sequence alignments versus rational design and directed evolution. , 2001, Current opinion in biotechnology.

[33]  A. Plückthun,et al.  Selecting proteins with improved stability by a phage-based method , 1998, Nature Biotechnology.

[34]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[35]  G. Weiss,et al.  Optimizing the affinity and specificity of proteins with molecular display. , 2006, Molecular bioSystems.

[36]  Michael V. Doyle,et al.  Semirational design of a potent, artificial agonist of fibroblast growth factor receptors , 1999, Nature Biotechnology.

[37]  G. Yancopoulos,et al.  Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering , 2003, Nature Structural Biology.

[38]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[39]  D. Ingber,et al.  A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. , 1988, The American journal of pathology.

[40]  John Sidney,et al.  Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.